Use of novel angiopoietin-1 mimetic peptide for the treatment of burn shock-associated endothelial dysfunction in severe burn injury

The Defense Health Agency awarded $1.696 million to Loyola University of Chicago Health Sciences Campus on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop and evaluate novel angiopoietin-1 mimetic peptides for treating burn shock-associated endothelial dysfunction in severe burn injury.

Work is performed at the Health Sciences Campus in Maywood, Illinois through August 31, 2029. The award funds biomedical research investigating medical solutions aligned with military relevance and Service Member health care innovation. Loyola University of Chicago, a private Jesuit research institution, operates the Health Sciences Campus as a division delivering organ transplant services and clinical research. The campus maintains active federal grant relationships across the National Institutes of Health, Defense Health Agency, and other agencies, with recent portfolio activity spanning immunology, infectious disease, cardiovascular disease, and translational medicine. This project grant is a competitive research award issued following two-tier peer and programmatic review by DHA scientists, federal agency representatives, and outside experts.